semaglutide black box warning The FDA sent a letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know Black box warning 101

InThought: After serving oncology spaces chronic lymphocytic leukemia and follicular lymphoma for well over a decade, obinutuzumab is now poised to enter the very challenging lupus market

Its almost never-ending. (The phenomenon of GLP-1s seemingly changing peoples skin is something Allure first reported on last summer.) Still, doctors generally agree that theres little hard evidenceas in, biopsy studies examining skin structure and function before and after GLP-1 useproving that these medications truly alter the tissues at a molecular level

GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: A randomized phase I trial

Many patients starting semaglutide or tirzepatide report feeling unusually cold, even in mild weathera side effect that can last weeks or months as their body adapts